Volpara Health Technologies
About Volpara Health Technologies
Volpara Health Technologies, now a wholly-owned subsidiary of Lunit Inc., is a global health technology company dedicated to saving families from cancer through its advanced AI-powered software solutions. For physicians, Volpara provides an integrated platform designed to optimize and personalize the cancer screening experience, primarily focusing on breast health. Its clinically validated algorithms leverage AI and machine learning to offer objective and quantitative analysis of breast tissue, including automated volumetric breast density assessment and comprehensive breast cancer risk assessment.
The platform also plays a crucial role in mammography quality assurance, providing real-time feedback to technologists on positioning, compression, and dose to ensure optimal image quality. This streamlines operations and delivers key performance insights for continuous quality improvement in breast imaging centers. Beyond breast cancer, Volpara’s capabilities are being extended to lung cancer screening, offering a broader approach to early cancer detection and personalized care. The software integrates seamlessly with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories, supporting over 2,000 facilities and impacting millions of patients globally.
Focus Areas
Business Intelligence
| Key Investors | Callaghan Innovation, Enterprise Angels, Horizon 3 Healthcare, Milford Asset Management, NorthStar Impact |
| Partnerships | Microsoft (for Azure data technology and AI development), Rezolut, Lunit (prior to acquisition, now parent company), American College of Radiology (ACR) ImPower Program, BOADICEA breast cancer risk model integration, U.S. Defense Health Agency (DHA) |
| Acquisitions | MRS Systems, Inc. (2019), CRA Health, LLC (2021), Acquired by Lunit Inc. (May 2024) |
| Technology | AI-powered software platform, cloud-native (utilizing Microsoft Azure), physics-based AI algorithms (Volpara TruDensity), Open Virtual Appliance (OVA) architecture |
| FDA Clearances | At least 6 FDA clearances (including initial Volpara Imaging Software in 2010, four additional clearances for the key science algorithm, and Volpara Density Maps/v3.1 in 2016, and VIS 3.2 in 2021) cleared products (estimated) |
What Physicians Need to Know
For physicians, Volpara Health Technologies stands out by providing objective, AI-driven insights that enhance clinical decision-making and streamline workflows. The precise volumetric breast density measurements (TruDensity) remove subjectivity, aiding in personalized screening recommendations and compliance with density reporting mandates. The mammography quality tools (TruPGMI) offer continuous, consistent feedback to technologists, leading to improved image quality and fewer technical recalls, which increases radiologists' reading confidence and efficiency. Volpara's comprehensive risk assessment (Risk Pathways) integrates various models and guidelines, allowing for proactive identification and management of high-risk patients, fostering better patient outcomes through tailored care pathways. The platform's ability to integrate seamlessly with existing EHRs and PACS systems minimizes administrative burden, freeing up time for patient dialogue and focused care. Furthermore, the extensive scientific validation and large dataset underpinning Volpara's algorithms provide a high level of trust and reliability in the clinical utility of their solutions.
Volpara Health's software is designed for seamless integration with various healthcare IT systems. It can be deployed stand-alone or fully integrated with Electronic Health Record (EHR) systems, mammography reporting systems, Picture Archiving and Communication Systems (PACS), imaging hardware from most digital mammography vendors, and genetic laboratories. The company utilizes a cloud-based platform, specifically Microsoft Azure, for secure data storage, analytics, and scalability, with strong information security certifications like ISO 27001. This multi-vendor and integrated approach ensures compatibility and efficient workflow within diverse clinical environments. Volpara Health has also recently been acquired by Lunit, indicating a future unified AI-powered breast ecosystem.
What the Web Says
Volpara Health Technologies develops AI-powered software for early breast cancer detection and mammography quality improvement. Their products, like Volpara Scorecard and Analytics, are widely used in cancer screening centers and are backed by extensive peer-reviewed research, making them a scientifically validated solution in breast health. While the company's mission and product impact are highly praised, employer reviews indicate mixed sentiment regarding internal management, training, and work-life balance, particularly in more recent reviews.
Overall: MixedStrengths
- Products enhance mammogram quality and facilitate early breast cancer detection.
- Scientifically validated with over 400 peer-reviewed papers.
- Objective and consistent breast density assessment, reducing variability.
- Dedicated to a noble cause (fighting cancer).
- Good benefits and hybrid work model reported by some employees.
- Strong market leadership and competitive advantages in breast density analysis and image quality solutions.
Limitations
- Lack of proper training for new hires and in technical support roles.
- Poor management and low morale reported by some employees.
- Engineers feeling overworked and underpaid.
- Company culture described as having poor communication, being fear-driven, and lacking transparency by some.
- High employee turnover and burnout mentioned in some reviews.
- Customer service/technical support management issues.
Based on reviews from: Indeed.com, Slashdot, Mucrama (investment analysis), Lunit (Volpara's acquirer, product page), Imaging Technology News, SourceForge, PR Newswire
Last updated: 2026-07-19
Videos
News, demos, and interviews about Volpara Health Technologies.
Videos load interactively. If none appear, search YouTube for Volpara Health Technologies →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]